Sometimes stabs at the future go wildly astray
From a Hancock column in December 2006, four months before AstraZeneca agreed to buy MedImmune:
Someday David Katz's wish will come true, and Abbott Laboratories or some other huge pharmaceutical company will buy MedImmune, Maryland's largest biotech company.MedImmune and Big Pharma each has something the other lacks. MedImmune has drugs in development that might someday be prescribed by doctors. Big Pharma has armies of salespeople who give doctors cool pens.But don't expect the match to happen for a long time.
Big Pharma isn't desperate enough to overpay for MedImmune, although it's getting closer. Gaithersburg-based MedImmune likes its chances as an independent, and so, apparently, do its shareholders.
